研究与报告
2026年8月30日•1 分钟阅读
Immunomic Therapeutics Completes First Patient Dosing in Phase 1 Trial of ITI-9001 for Japanese Cedar Pollen Allergy
Immunomic Therapeutics reported first patient dosing in a Phase 1 trial of ITI-9001, a Japanese cedar pollen allergy vaccine, with no safety issues observed.
研究与报告
2026年8月24日•1 分钟阅读
PMDA Workshop on New Approach Methodologies (NAMs) Held after ICCR‑20
The Pharmaceuticals and Medical Devices Agency (PMDA) held a workshop on New Approach Methodologies (NAMs) following the ICCR‑20 symposium.
1
研究与报告
2026年8月23日•1 分钟阅读
PMDA Concludes MoU with London School of Hygiene & Tropical Medicine
The Pharmaceuticals and Medical Devices Agency (PMDA) has signed a Memorandum of Understanding with the London School of Hygiene & Tropical Medicine to promote joint work in pharmaceutical research and regulatory science.